Table 5.
Specific inconsistencies in PGx recommendations for drug–gene pairs with recommendations from all three sources: CPIC, FDA, and professional CPGs.
| Drug–gene pair | Specific types of inconsistencies present | ||||
|---|---|---|---|---|---|
| Biomarker/gene | Recommendation category | Clinically actionable | Recommendation group | Routine screen | |
| Abacavir/HLA-B | |||||
| Azathioprine/TPMT | X | X | X | X | X |
| Capecitabine/DPYD | X | X | X | X | |
| Citalopram/CYP2C19 | X | X | X | X | |
| Clopidogrel/CYP2C19 | X | X | X | ||
| Fluorouracil/DPYD | X | X | X | ||
| Fluvoxamine/CYP2D6 | X | X | X | X | |
| Ivacaftor/CFTR | X | X | |||
| Mercaptopurine/TPMT | X | X | X | ||
| Paroxetine/CYP2D6 | X | X | X | X | |
| Sevoflurane/RYR1 | X | X | X | ||
| Tamoxifen/CYP2D6 | X | X | X | X | |
| Voriconazole/CYP2C19 | X | X | X | ||
| Warfarin/CYP2C9 | X | X | X | X | |
| Warfarin/VKORC1 | X | X | X | X | |
CPG clinical practice guidelines for professional medical organizations, CPIC Clinical Pharmacogenetics Implementation Consortium, FDA U.S. Food and Drug Administration.
Marked boxes indicate the presence of the respective.